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doi:10.1016/j.ejvs.2010.10.005Abstract Objective: The aim of our study was to evaluate the effectiveness of in situ revas-
cularisation with the use of arterial homografts and silver-coated prostheses in the treatment
of aortic graft infection.
Materials: A total of 77 consecutive patients (74 males, three females, mean age: 58 years),
hospitalised between 2001 and 2008, were enrolled into the study. Patients were assigned
to three groups: group 1 (nZ 24) e fresh arterial homograft with subsequent immunosuppres-
sion, group 2 (n Z 26) e fresh arterial homograft without immunosuppression and group 3
(n Z 27) e silver-coated prosthesis.
Methods: The course of infection was assessed by scintigraphy with 99mTechnetium-labelled
leucocytes, DuplexeDoppler ultrasound, angio-computed tomography (CT) and microbiological
examination.
Results: The mean follow-up was 22.8 (10.1) months. There was a significant decrease in leu-
cocyte accumulation around the graft among all groups (group 1: p Z 0.012, group 2:
p Z 0.006 and group 3: p Z 0.021). The postoperative mortality rate in groups 1,2 and 3
was 8%, 23% and 11%, respectively. The postoperative morbidity was 35% in group 2, 16% in
group 1 and 7% in group 3.
Conclusion: Our study suggests that silver-coated prostheses can be as effective as arterial
allografts in the treatment of infections of vascular prostheses.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.1739126; fax: þ48 717332009.
wroc.pl (A. Pupka).
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Infections following vascular procedures, particularly those
requiring implantation of artificial components, constitute
one of the most concerning problems in vascular surgery.1
Severe infection may be not only disabling but also a deadly
complication.1,2 The number of patients treated by implan-
tation of artificial prostheses is constantly growing, and that is
why the problem of the infection of prostheses has become
more common. Excision of the infected material and re-
establishment of bloodflow remains a therapyof choice in this
group of patients.16 For vascular reconstructions, arterial
and venous autografts are used as well as homografts har-
vested from organ donors.1,2 Implantation of a tissue graft in
place of a synthetic material improves the process of healing.
If a suitable autologous or homologous graft is not available, a
synthetic, infection-resistant material is used, for example,
polytetrafluoroethylene (PTFE) or regular Dacron prostheses,
impregnated with antibiotics such as rifampicin, mupirocin
and antimicrobial agents such as triclosan.3,4,716 Silver-
coated materials are also widely used in vascular surgery.17
Polyester, bovine collagen-sealed and silver-coated pros-
theses are also currently used in vascular reconstructive
surgery.18,19 Silver acetate inhibits bacterial colony formation
on the vascular prosthesis surface and surrounding tissues
during the postoperative period. It’s antimicrobial properties
and lack of local and systemic toxicity have been proven by
both in vitro and in vivo studies.5,17,20 One clinical trial has
been carried out to verify the effectiveness of vascular pros-
thesis infection treatment with the use of in situ silver-coated
prosthesis; however, no controlswereavailable in this study.18
The aim of our research was to compare three methods of
treatment used in vascular prostheses infections: implanta-
tionof silver-coatedDacronprosthesesandarterial homograft
transplantation with or without simultaneous immunosup-
pressive therapy.
Materials and Methods
A prospective, non-randomised clinical study was carried out.
A total of 77 patients were admitted to our clinic and treated
surgically due to severe vascular prosthesis infection, from
2001 to 2008. The mean time (SD) of the follow-up was 22.8
(10.1) months. A long-term follow-up was completed for 13
patients from group 1, 14 from group 2 and 17 from group 3.
The diagnosis in each case was established by clinical and
radiological findings, such as purulent fistulas to the skin and/
or perigraft fluid. In the majority of patients (n Z 73), the
infection was complicated by the splitting apart of vascular
anastomoses and concomitant bleeding. Surgical therapy
comprised the replacement of the infected vascular pros-
thesis for an arterial homograft, preserved by means of cold
ischaemia (nZ 50) with (nZ 24) or without (nZ 26) immu-
nosuppressive therapy. According to the protocol approvedby
the Bioethics Committee of the University of Medicine of
Wroclaw, patients decided whether they wanted to take
cyclosporin A after obtaining detailed information about the
possible benefits and risks. When none of the above methods
were available (no donor or patient did not agree for arterial
transplantation from a dead donor), implantation of a poly-
ester, collagen-sealed, silver-coated prosthesis (nZ 27) wascarried out. The study was approved by the Institutional
Review Committee and the Bioethics Committee of the
Medical University of Wroclaw. Patients were assigned to
three groups:
 group 1 (n Z 24) consisted of patients treated with
fresh arterial homograft implantation followed by
immunosuppressive therapy (Table 1);
 group 2 (n Z 26) consisted of patients treated with
fresh arterial homograft implantation without immu-
nosuppressive therapy (Table 1); and
 group 3 (n Z 27) consisted of patients treated with
Dacron, collagen-sealed, silver-coated prosthesis
implantation (Table 1).
The immunosuppressive protocol implemented in group 1
was based on the administration of cyclosporin A
(Sandimmun; Novartis Pharma GmbH) in daily doses of
1e3 mg per kg of body mass. The serum concentration of
cyclosporin A was determined to establish its level between
120 and 140 ng per ml of the patient’s serum. An intravenous
infusionof cyclosporinAwas started intra-operatively, shortly
after successful revascularisation. On discharge, patients
were prescribedoral cyclosporin (SandimmumNeoral) in daily
doses of 1e3 mg per kg of body mass, adjusted to every
patient, according to the serum cyclosporin concentration.
The drugs were taken by the patients until the end of the
study. In the first group, 19 Y-shaped homografts were trans-
planted (in four cases to treat graft duodenal fistula, GDF).
The remaining patients received four iliofemoral and one
aortofemoral bypass. The time of simple hypothermia pres-
ervation of aortic homografts did not exceed 24 h. Cultures of
specimens collected from the inguinal area, retroperitoneal
space and excised prosthesis revealed methicillin-resistant
Staphylococcus aureus(MRSA) infection in 22 patients (92%),
Staphylococcus epidermidis infection in 10 patients (42%) and
Pseudomonas aeruginosa in seven cases (29%).
Patients from group 2 did not receive immunosuppressive
treatment. A total of 22 Y-shaped homografts (in five cases to
treat GDF) and four iliofemoral bypasseswere used. The time
of homograft preservation by means of cold ischaemia did
not exceed 22 h. The cultures of specimens collected from
the inguinal area, retroperitoneal space and prosthesis wall
were positive for MRSA in 21 (81%) patients, S. epidermidis in
nine (35%) and P. aeruginosa in five (19%) patients.
Group 3 comprised of those patients, who received
Dacron, collagen-sealed, silver-coated prostheses (Inter-
Gard Silver prosthesis; InterVascular, La Ciotat, France) in
place of the excised prosthesis. Silver-coated grafts were
used when no homografts were available, the patient did
not agree for arterial transplantation from a dead donor, the
possibility of inserting extra-anatomic bypasses was ruled
out and when patient’s condition was too serious to wait for
the fresh arterial homograft. Fourteen patients received
aortobifemoral prostheses (Y-shaped grafts of 16/8 mm and
18/8 mm). Straight aortic prostheses (Øe18 and 20 mm)
were implanted in seven patients, whereas six patients
received iliofemoral bypasses (Øe8 mm). Microbial cultures
from the periprosthesis site and the sites of peripheral
anastomoses showed MRSA to be a leading aetiological
factor of infections in 25 (93%) patients. S. epidermidis was
cultured in 10 (37%) cases.
Table 1 Characteristics of patients with an infection of the vascular prosthesis.
Characteristics of patients with prosthetic graft infections Group 1 (N Z 24) Group 2 (N Z 26) Group 3 (N Z 27)
Age (years, mean  SD) 42e68 (57.4  5.6) 50e71 (59.2  4.7) 52e65 (58.4  3.7)
Male 23 24 27
Female 1 2 e
Primary operation
Atherosclerosis 24 (100%) 25 (96%) 19 (70%)
Y prosthesis 19 21 13
By-pass 5 4 6
Aortic aneurysm e 1 (4%) 8 (30%)
Y prosthesis e 1 1
Straight prosthesis e e 7
Additional illnesses
Diabetes 7 (29%) 8 (31%) 7 (26%)
Ischemic heart disease 13 (54%) 14 (54%) 14 (52%)
Renal failure 4 (17%) 4 (15%) 3 (11%)
Leg necrosis 7 (29%) 6 (23%) 10 (37%)
Manifestation of the infection
Fluid around the prosthesis 24 (100%) 26 (100%) 27 (100%)
Purulent fistula 24 (100%) 26 (100%) 20 (74%)
Aortic pseudoaneurysm 15 (63%) 17 (65%) 11 (41%)
Peripheral pseudoaneurysm 16 (67%) 14 (54%) 16 (59%)
Bleeding from the vascular anastomosis 24 (100%) 22 (85%) 27 (100%)
Graft duodenal fistula (GDF) 4 (17%) 5 (19%) 9 (33%)
Infection seen in scintigraphy 24 (100%) 26 (100%) 27 (100%)
Infection confirmed by the bacteriological examination 24 (100%) 26 (100%) 27 (100%)
Symptoms of sepsis 10 (42%) 8 (31%) 9 (33%)
In Situ Revascularisation with Silver-coated Polyester Prostheses and Arterial Homografts 63In each case, the infection was confirmed with duplexe
doppler ultrasound, computed tomography (CT) and scintig-
raphy using 99mTechnetium-labelled leucocytes. All the
patients received antibiotics (vancomycin, ciprofloxacin and
imipenem) before and for a period of up to 30 days after the
surgery. Antibacterial therapy protocols were designed
according to antibiograms. Broad-spectrum protocols were
applied when microbiological examination was of limited
reliability.
Diagnosis and indication for surgical intervention in
patients with localised vascular prosthesis infection (nZ 6)
were established by means of scintigraphy with 99mTech-
netium-labelled leucocytes. Four of these patients were
treated by removing the infected part of the Y-shaped
prosthesis and replacing its branch with a homograft bypass
(n Z 4, one patient suffering from MRSA infection, three
patients with S. epidermidis infection). If that type of
treatment was not available, a silver-coated graft was
implanted (n Z 2; Ø Z 8 mm; one patient with MRSA and
one patient with S. epidermidis infection). In the cases
where fresh arterial homografts were used, the immuno-
suppression protocol was implemented.
Arterial homografts were collected from dead donors
with a confirmed brain death. During this procedure, a frag-
ment of an arterywas taken for amicrobiological evaluation.
Homografts were preserved in the UW (University of Wis-
consin) fluid.Tissue histocompatibility (A and B loci from class I
human leucocyte antigen (HLA) and D locus from class II
HLA), ABO compatibility and a cross-match were carried
out in every patient from groups 1 and 2. Virological and
serological examinations were performed in each donor
(anti-human immunodeficiency virus (HIV), hepatitis B
surface (HBs)-Ag, anti-HB core (HBc), anti-hepatitis C virus
(HCV), anti-EpsteineBarr virus (EBV), HbeeAg, anti-cyto-
megalovirus (CMV) and Venereal Disease Research Labora-
tory (VDRL) test). There was no statistical difference
in tissue histocompatibility between groups 1 and 2.
All homografts were evaluated before implantation using
scanning electron microscopy. In each case, the examina-
tion revealed a non-damaged arterial wall and presence of
intact endothelium.
Postoperative treatment, the intensity of infection and
the effects of the therapy were monitored by means of
scintigraphy. In some patients, the microbiological exami-
nation was carried out repeatedly. Before and after the
operation, CT, duplexedoppler ultrasound, and, in some
cases, angiography, were performed.
The primary endpoint was the recurrence of infection,
confirmed by clinical and laboratory examinations or by
scintigraphy, which lead to surgical intervention. Secondary
endpoints were early and late postoperative morbidity and
mortality, amputations, graft patency, rupture of the graft
and presence of the graft aneurysm.
Figure 1 KaplaneMeier survival analysis of the patients.
Table 3 Postoperative morbidity.
Postoperative Group 1 Group 2 Group 3
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tistica 5.5 software. The results were analysed by para-
metrical and non-parametrical tests such as chi-square,
chi-square analysis of variance (ANOVA) and the Utest of




The highest mortality rate (35%) was noted in group 2,
where no immunosuppression was used (Table 2, Fig. 1).
However, as far as all groups are concerned, a comparative
study did not show any statistical differences in post-
operative mortality (p Z 0.14).
One patient from group 1 died in the early postoperative
period due to septic shock and another patient 11 months
after operation (cerebrovascular accident). Four patients
from group 2 died in the early postoperative period (septic
shock, myocardial infarction and two cases of GDF), and two
patients died in the late postoperative period due to rupture
of the implanted arterial homograft (graft aneurysm).
Among patients from group 3, where silver-coated
prostheses were used, two patients died in the early post-
operative period. The first incident was due to multiple-
organ failure secondary to septic shock and occurred on the
first postoperative day. The second case was caused by bile
leakage as a result of the duodenal anastomosis split on the
ninth postoperative day. One patient died 9 months after
the surgery due to recurrent GDF. As this happened outside
our clinic, the circumstances of this event remain unclear.
Despite the fact that no autopsy was performed, the
laconic postoperative report seems to point to infection as
a leading cause of this adverse event.
Postoperative morbidity
During the early postoperative period, no cases of lower-
extremity ischaemia were observed. The DuplexeDoppler
examination revealed normal blood flow in aortobifemoral
prostheses and profound femoral arteries in all patients.
Clinical signs of early reinfection were noted only in one
patient (4%) from group 1 (Table 3, Fig. 2). Healing by first
intention of surgical wounds was observed among allTable 2 Postoperative mortality.






Early<30 days 1 (4%) 4 (15%) 2 (7%)
Septic shock 1 (4%) 1 (4%) 1 (4%)
Graft duodenal fistula 2 (8%) 1 (4%)
Myocardial infarction e 1 (4%) e
Late>30 days 1 (4%) 2 (8%) 1 (4%)
Recurrence of graft
duodenal fistula
e e 1 (4%)
Rupture of graft e 2 (8%) e
2 (8%) 6 (23%) 3 (11%)subjects. There was one case (4%) of upper-extremity isc-
haemia in group 1 due to thrombosis in the first post-
operative month.
Late reinfection was observed in one patient (4%) from
group 2 and one patient from group 3. Lower-extremity
ischaemia was noted in two patients from group 1, but it
was not probably associated with the operation (athero-
sclerosis of femoral and popliteal arteries).
Thrombotic complications in group 3 were seen in one
patient during the third month after implantation of aor-
tobifemoral, silver-coated prosthesis. In this case, one
limb of the silver-coated graft was obliterated by throm-
botic material. A perigraft fluid space limited to the
inguinal area was observed. Microbial cultures of collected
specimens revealed strains of S. epidermidis. In spite of an
early surgical intervention, due to propagation of arterial
thrombosis spread to peripheral leg segments, conse-
quently leading to ischaemia, amputation was performed
on the third postoperative day. Amongst other patients in
this group, where careful ultrasonographic assessment
of implanted prostheses was completed, perigraft fluid
spaces were not seen, and positive blood cultures were notcomplications (N Z 24) (N Z 26) (N Z 27)




1 (4%) e e
Thrombosis 1 (4%) e e
Late>30 days 2 (8%) 9 (35%) 2 (7%)
Lower extremity
ischaemia
2 (8%) e e
Graft thrombosise
amputation
e 3 (12%) 1 (4%)
Reinfection e 1 (4%) 1 (4%)
Rupture of graft e 3 (12%) e
Graft aneurysm e 2 (8%) e
4 (16%) 9 (35%) 2 (7%)
Figure 2 Period free from surgical intervention (KaplaneMe-
ier analysis).
Figure 4 Regression of infection among patients from group
2 e treated with a homograft transplantation without immu-
nosuppressive therapy.
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in group 2, which led to surgical intervention.
Five patients from group 2 suffered from homograft
aneurysm. In three cases, aneurysms ruptured, and, in two
cases, the aneurysms were excised before they ruptured.
A comparative investigation of the number of all post-
operative complications between the studied groups
showed statistically significant difference between groups 2
(35%) and 3 (7%) (p < 0.015). No differences between
groups were observed as far as early complications were
concerned. The incidence of late complications was the
highest in group 2, in which homograft implantation was not
followed by any immunosuppressive protocol (statistically
significant differences were seen between groups 1 and 2
(p < 0.025), and groups 2 and 3 (p < 0.015)).
Laboratory and radiological examination results
Laboratory and radiological examinations confirmed the
regression of infection shortly after the operation in all
patients. The ultrasound examination showed no evidenceFigure 3 Regressionof infection inscintigraphyamongpatients
from group 1 e treated with a homograft transplantation and
immunosuppressive drugs.of fluid space around the homografts and silver-coated
prostheses in all cases. Scintigraphy revealed the statis-
tically significant (group 1: p Z 0.012, group 2: p Z 0.006
and group 3: p Z 0.021) decrease of accumulation of the
99mTc-labelled leucocytes around the homograft in all
groups, during the whole observation period of 27 months
(Figs. 3e5). The biggest drop in the area of accumulated
leucocytes was in the sixth postoperative month (Figs.
3e5). The highest rate of decrease was observed in
group 1, but the difference between groups was statisti-
cally non-significant (pZ 0.24). The total reduction of the
area of accumulation of the 99mTc-labelled leucocytes
during the postoperative period was 37% in group 1, 44% in
group 2 and 40% in group 3. The statistically significant
difference in the area of accumulation was observed only
between groups 1 and 2, 18 months after the operation
(p Z 0.016), and it was bigger in group 2.
Follow-up of patients treated with localised replacement
of infected vascular grafts also showed regression of scinti-
graphic signs of infection (Figs. 3e5). The most convincing
therapy effect was noticed among patients treated withFigure 5 Regression of infection among patients of group
3 e treated with a silver-coated, collagen-bonded prosthesis
implantation.
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lation decreased by 34%. Amongst patients treated with
silver-coated, collagen-bonded prostheses, the decrease of
the accumulation areawas 17%.However,wedid not observe
higher incidence of reinfection in this group.
Whenever there was no improvement in leucocyte acc-
umulation, antibiotics were administered. This took place
four times in group 1 (16%) and three times in group 2 (11%).
The antibacterial treatment resulted in the reduction of
the leucocyte accumulation.Discussion
The axillofemoral, extra-anatomic bypassing technique,
which was generally considered the gold standard in the
treatment of aortic prosthesis infections, has recently been
proven less effective than the in situ revascularisation
procedure.2123 The intensity of synthetic prosthesis inf-
ections in our study was defined as third degree, according
to the Szilagy scale, and fifth degree according to the
Samson scale.24 Replacement of an infected prosthesis with
an arterial homograft is regarded as the therapy of choice in
this life-threatening condition.21,22 We chose cold-preserved
fresh arterial homografts (4 C), as it appeared to us that the
deep-freezing method was more likely to decrease perma-
nence of the arterial wall and cause endothelial degrada-
tion.6,17 If the arterial homograft revascularisation was not
an option for our patients, silver-coated prostheses were
used.
There is a lack of clinical trials validating the use of silver-
coated grafts performed on a representative sample of
patients, and further clinical testing is needed.20,21,26 Her-
nandezeRichter et al. claim, based on their experimental
studies, that silver-coated grafts have little or no antibac-
terial activity.26 On the other hand, bacterial resistance to
antibiotics emerges faster than to antiseptics. Beside the
questionable nature of using silver-coated biomaterials,
many studies presented arguments for its use in a bacterial-
infected environment.18,19,26
In this setting, tissuematerial remains a graft of choice, as
it shows the best anti-infection resistance. Frequency of
reinfection is significantly lower than using artificial pros-
theses.21,22,25 The problem of tissue-graft rejection led us to
conclude that the proper transplantation protocol should be
instituted. Procedures of harvesting, preservation and tissue-
compatibility determination were designed and carried out
for arterial homografts. There is also a new generation of
silver-coated prostheses entering the market. If a decreased
incidence of infectionwith these new products is achieved, it
could prove to be a good alternative method to arterial
homografts, as there may be no need for the implementation
of immunosuppressive protocols.
For carrying out a comparative study of the intensity of
inflammation after surgical management of the infected
vascular prosthesis, we used lymphocyte Tc-labelled scin-
tigraphy. It allowed careful assessment of periprosthetic
inflammation processes. Each time there was no decrease
in the accumulation of leucocytes, antibiotics were given to
the patient. The antibacterial treatment resulted in the
reduction of leucocyte accumulation. If there were no
clinical signs of reinfection, scintigraphy was a very usefulmethod for detecting the infection at an early stage.
Increased migration of lymphocytes to the operated area
may also be explained as a reaction to the implanted arti-
ficial body (Dacron, homograft). However, in this setting,
the administration of antibiotics decreased the accumula-
tion of leucocytes, which suggests that infection caused the
inflammatory process and migration of the lymphocytes.
A smaller decrease in lymphocyte accumulation around
silver-coated prosthesis than around arterial homografts may
validate the theory of its higher susceptibility to infection.
Nevertheless, this had no impact on the clinical status of our
patients. A nearly 2-year long follow-up period did not show
higher mortality or a higher incidence of other complications
in the group treated with silver-coated prostheses in
comparison to those treated with arterial homografts.
Conclusions
Our results are based on the analysis of patients treated in
a single clinical centre. That allowed us to minimise
potential procedural mistakes, which seem to burden
multicentre studies. Our study suggests that silver-coated
prostheses can be as effective as arterial allografts in the
treatment of infections of the vascular prostheses, and, for
this reason, we conclude that if no homograft is available,
silver-coated prosthesis implantation can be a good treat-
ment option. However, a randomised clinical trial con-
cerning more treatment options is needed for more
accurate evaluation of the safety and long-term effec-
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